Page last updated: 08/26/2020
In this phase 2, single-arm, multi-cohort trial the safety and efficacy of tepotinib, an oral and once-daily METMET geneA gene that makes a protein called MET, which is involved in sending signals within cells and in cell growth and survival. Mutated (changed) forms of the MET gene may cause abnormal cells to grow and spread in the body.5 inhibitor, is investigated in patients with advanced or metastatic NSCLCNon-small cell lung cancerNon-small cell lung cancer is the most common kind of lung cancer. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.6 harboring MET alterationsMETex14 skippingWhen METex14 skipping mutations occur in the MET gene, an abnormal MET receptor is produced in which the exon 14 part is mistakenly deleted. As a result, the abnormal MET receptor is not removed from the cell surface, leading to an excess of MET receptors on the surface that continually transmit growth signals, thereby driving cancer.7.
The trial will measure:*
*For a full list of all outcome measures, inclusion and exclusion criteria, please visit clinicaltrials.gov, NCT02864992.
* Target enrollment.
** Treatment continues until progression of disease, withdrawal of consent, or development of unacceptable toxicities. It is 500 mg tepotinib hydrochloride hydrate which is equivalent to 450 mg tepotinib (the free base form).
DOR: duration of response; DC: disease control; PFS: progression-free survival; OS: overall survival; HRQOL: health-related quality of life
Speak with a doctor to see if a clinical trial is the right option for you.
Tepotinib is being investigated in this clinical trial and under clinical investigation in several countries of the world. This page describes one of the clinical trials for tepotinib, and it includes information about how the safety and efficacy of tepotinib will be measured and evaluated. Safety and efficacy of tepotinib have to be investigated following the respective local regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the competent health authority in your country.
Patients should speak with their doctors, who can help determine if a clinical trial might be the right option. Doctors will be able to answer patients' questions about the risk of participating in a trial, and what other options may be available to you.
1 ClinicalTrials.gov. Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations (VISION). https://clinicaltrials.gov/ct2/show/NCT02864992. Accessed April 3, 2020.
2 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/advanced-cancer. Accessed April 5, 2020.
3 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/799321. Accessed April 5, 2020.
4 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/monotherapy. Accessed April 7, 2020.
5 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/794425. Accessed April 7, 2020.
6 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/non-small-cell-lung-cancer. Accessed April 7, 2020.
7 Drilon A et al. J Thorac Oncol. 2017;12:15-26.
8 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/performance-status. Accessed April 7, 2020.
9 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/egfr. Accessed April 7, 2020.
10 National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/alk-gene. Accessed April 7, 2020.